Longeveron, Inc. (LGVN)
2.435
-0.04
(-1.81%)
USD |
NASDAQ |
Oct 12, 16:00
2.435
0.00 (0.00%)
After-Hours: 20:00
Longeveron Enterprise Value : -1.630M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | -1.630M |
| October 08, 2026 | -1.979M |
| October 07, 2026 | -1.757M |
| October 06, 2026 | -2.042M |
| October 05, 2026 | -1.534M |
| October 02, 2026 | -1.312M |
| October 01, 2026 | -1.281M |
| September 30, 2026 | -0.9636M |
| September 29, 2026 | -0.8684M |
| September 28, 2026 | -1.154M |
| September 25, 2026 | -0.583M |
| September 24, 2026 | -0.2658M |
| September 23, 2026 | -1.249M |
| September 22, 2026 | -0.8684M |
| September 21, 2026 | -1.725M |
| September 18, 2026 | -1.598M |
| September 17, 2026 | -0.9002M |
| September 16, 2026 | 11.69M |
| September 15, 2026 | 12.26M |
| September 14, 2026 | 12.45M |
| September 11, 2026 | 13.75M |
| September 10, 2026 | 11.57M |
| September 09, 2026 | 11.38M |
| September 08, 2026 | 11.60M |
| September 04, 2026 | 12.10M |
| Date | Value |
|---|---|
| September 03, 2026 | 11.38M |
| September 02, 2026 | 12.01M |
| September 01, 2026 | 11.91M |
| August 31, 2026 | 12.39M |
| August 28, 2026 | 11.82M |
| August 27, 2026 | 12.07M |
| August 26, 2026 | 12.81M |
| August 25, 2026 | 12.07M |
| August 24, 2026 | 17.08M |
| August 21, 2026 | 17.30M |
| August 20, 2026 | 16.77M |
| August 19, 2026 | 16.59M |
| August 18, 2026 | 15.47M |
| August 17, 2026 | 16.51M |
| August 14, 2026 | 13.97M |
| August 13, 2026 | 12.63M |
| August 12, 2026 | 14.19M |
| August 11, 2026 | 12.46M |
| August 10, 2026 | 13.86M |
| August 07, 2026 | 14.80M |
| August 06, 2026 | 15.04M |
| August 05, 2026 | 13.57M |
| August 04, 2026 | 14.04M |
| August 03, 2026 | 13.72M |
| July 31, 2026 | 12.75M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.631B |
| Oncolytics Biotech, Inc. | 65.76M |
| Sangamo Therapeutics, Inc. | 52.97M |
| Sarepta Therapeutics, Inc. | 2.143B |
| Anixa Biosciences, Inc. | 85.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.073M |
| Revenue (Quarterly) | 0.287M |
| Total Expenses (Quarterly) | 6.36M |
| EPS Diluted (Quarterly) | -1.936 |
| Gross Profit Margin (Quarterly) | -13.59% |
| Profit Margin (Quarterly) | -2.12K% |
| Earnings Yield | -416.9% |
| Normalized Earnings Yield | -416.86 |